Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “solriamfetol” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 13
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 13 pipeline programs matching "solriamfetol" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

13 results for “solriamfetol” Back to intelligence hub

Search results

  1. SOL-BED-303

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial
  2. Solriamfetol

    Ignis Therapeutics (Suzhou) Limited

    Sleep Apnea, Obstructive

    phase 3 small molecule completed

    1 trial
  3. Solriamfetol 150 MG

    Axsome Therapeutics

    Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

    phase 3 small molecule active

    1 trial
  4. Solriamfetol 150 mg

    Axsome Therapeutics

    Excessive Sleepiness

    phase 3 small molecule active

    1 trial
  5. Solriamfetol 150 mg

    Axsome Therapeutics

    ADHD

    phase 3 small molecule completed

    1 trial
  6. Solriamfetol 150 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial
  7. Solriamfetol 300 mg

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial
  8. Solriamfetol

    Axsome Therapeutics

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  9. Solriamfetol 150 mg Oral Tablet

    Axsome Therapeutics

    Narcolepsy

    phase 1 small molecule completed

    1 trial
  10. Solriamfetol

    Jazz Pharmaceuticals Ireland Limited

    Binge Eating Disorder

    approved small molecule active

    1 trial
  11. Solriamfetol

    Axsome Therapeutics

    Excessive Daytime Sleepiness

    approved small molecule completed

    1 trial
  12. Solriamfetol 75 MG

    Axsome Therapeutics

    Insomnia

    approved small molecule completed

    1 trial
  13. Solriamfetol Oral Tablet

    Axsome Therapeutics

    Excessive Sleepiness

    approved small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.